- Home
- ATAT vs RNA Comparison
ATAT vs RNA Comparison
Compare ATAT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- RNA
- Stock Information
- Founded
- ATAT 2013
- RNA 2012
- Country
- ATAT China
- RNA United States
- Employees
- ATAT N/A
- RNA N/A
- Industry
- ATAT Hotels/Resorts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- RNA Health Care
- Exchange
- ATAT Nasdaq
- RNA Nasdaq
- Market Cap
- ATAT 4.0B
- RNA 3.2B
- IPO Year
- ATAT 2022
- RNA 2020
- Fundamental
- Price
- ATAT $23.94
- RNA $26.66
- Analyst Decision
- ATAT Strong Buy
- RNA Strong Buy
- Analyst Count
- ATAT 1
- RNA 12
- Target Price
- ATAT $36.80
- RNA $68.25
- AVG Volume (30 Days)
- ATAT 1.9M
- RNA 1.9M
- Earning Date
- ATAT 05-22-2025
- RNA 05-08-2025
- Dividend Yield
- ATAT 1.88%
- RNA N/A
- EPS Growth
- ATAT 71.91
- RNA N/A
- EPS
- ATAT 1.26
- RNA N/A
- Revenue
- ATAT $992,989,819.00
- RNA $10,897,000.00
- Revenue This Year
- ATAT $27.87
- RNA N/A
- Revenue Next Year
- ATAT $21.97
- RNA $135.33
- P/E Ratio
- ATAT $19.03
- RNA N/A
- Revenue Growth
- ATAT 55.34
- RNA 13.98
- 52 Week Low
- ATAT $15.22
- RNA $21.51
- 52 Week High
- ATAT $33.32
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- ATAT 36.35
- RNA 45.21
- Support Level
- ATAT $21.50
- RNA $25.28
- Resistance Level
- ATAT $24.76
- RNA $27.67
- Average True Range (ATR)
- ATAT 1.72
- RNA 2.36
- MACD
- ATAT -0.27
- RNA -0.03
- Stochastic Oscillator
- ATAT 30.07
- RNA 56.41
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.